Lee Jason K H, Lam Gary K L, Yin J Kevin, Loiacono Matthew M, Samson Sandrine I
Leslie Dan School of Pharmacy, University of Toronto, Toronto, ON, Canada.
Sanofi, Toronto, ON, Canada.
Vaccine X. 2023 Jun 5;14:100327. doi: 10.1016/j.jvacx.2023.100327. eCollection 2023 Aug.
This updated systematic review and -analysis of randomized and observational studies published up to April 2023 assessed the relative performance of high-dose inactivated influenza vaccine (HD-IIV) and standard-dose influenza vaccines (SD-IIV) against influenza-associated outcomes in older adults (≥65 years). The analysis included studies conducted over 12 influenza seasons (2009/2010 to 2019/2020, 2021/2022), including over 45 million individuals aged ≥ 65 years, and showed that HD-IIV provided significantly better protection than SD-IIV against influenza-like illness and influenza-related hospitalizations, as well as cardiovascular, cardiorespiratory, and all-cause hospitalizations. Subgroup analyses showed HD-IIV consistently provided better protection than SD-IIV against influenza outcomes across the age range (65+, 75+ 85+ years), and regardless of the predominantly circulating influenza strain and vaccine antigenic match/mismatch. Randomized studies continue to drive high-quality evidence on the effectiveness of high-dose inactivated influenza vaccine relative to SD-IIV against severe influenza outcomes in adults aged ≥ 65 years, supported by observational data.
本项对截至2023年4月发表的随机研究和观察性研究进行的系统综述及分析，评估了高剂量灭活流感疫苗（HD-IIV）和标准剂量流感疫苗（SD-IIV）在老年人（≥65岁）中预防流感相关结局的相对效果。该分析纳入了在12个流感季节（2009/2010至2019/2020、2021/2022）开展的研究，涉及超过4500万≥65岁的个体，结果显示HD-IIV在预防流感样疾病、流感相关住院以及心血管、心肺和全因住院方面比SD-IIV提供了显著更好的保护。亚组分析表明，HD-IIV在整个年龄范围（65岁以上、75岁以上、85岁以上），无论主要流行的流感毒株以及疫苗抗原匹配/不匹配情况，始终比SD-IIV在预防流感结局方面提供更好的保护。随机研究继续为高剂量灭活流感疫苗相对于SD-IIV在≥65岁成年人中预防严重流感结局的有效性提供高质量证据，并得到观察性数据的支持。
